Down syndrome regression disorder responsive to immunoglobulin modulation therapy
Down syndrome (DS), caused by trisomy 21 in ~95% of cases, carries three copies of the chromosome 21 interferon receptor cluster (IFNAR1, IFNAR2, IFNGR2, and IL10RB), leading to a constitutive, mild interferonopathy across types I, II, and III signalling. Down syndrome regression disorder (DSRD) is a devastating neuro-regression occurring between 10 and 30 years. A sub-group shares immunological and neuroimaging features with the monogenic type I interferonopathies, though the mechanism differs: trisomy 21 confers receptor-level over-responsiveness rather than ligand excess. DSRD remains a diagnosis of exclusion but commonly arises on a background of pre-existing neurodevelopmental or neuropsychiatric comorbidity, so identifying a comorbidity does not itself exclude it. Both adolescents described here presented with severe neuropsychiatric regression, symmetric basal ganglia mineralization, and an isolated elevation of the interferon-stimulated gene IFI27. No commissioning pathway for DSRD immune-directed therapy exists in the United Kingdom (UK). Approximately 21 months after onset, intravenous immunoglobulin (IVIG) was commenced in both, for the first time in the UK: 2 g/kg loading then eight monthly doses of 1 g/kg. Nine doses produced partial but clinically meaningful multidomain improvement without serious adverse events. Serial IFI27 fell in both but remained above the reference interval throughout; it did not track clinical response. These descriptive observations require confirmation in controlled studies. Inability to access workup and treatment is a health inequity; early recognition and a multidisciplinary approach spanning neurology, psychiatry, and immunology are needed.
Authors
- Olivier Broucke
- Kimberly Gilmour (ORCID: https://orcid.org/0000-0003-0285-3958)
- Konstantinos Vazouras (ORCID: https://orcid.org/0000-0002-5278-0083)
- Iek Leng Cheng (ORCID: https://orcid.org/0000-0003-1010-8085)
- E. S. Rachamim
- Ashley Liew (ORCID: https://orcid.org/0000-0002-3825-225X)
- Shahid H. Zaman (ORCID: https://orcid.org/0000-0003-1639-6014)
- Paramala Santosh (ORCID: https://orcid.org/0000-0003-4830-5893)
- Kshitij Mankad (ORCID: https://orcid.org/0000-0001-5979-9337)
- Marios Kaliakatsos (ORCID: https://orcid.org/0000-0001-6299-9866)
- Eleanor J. Molloy (ORCID: https://orcid.org/0000-0001-6798-2158)
- Maaike Kusters (ORCID: https://orcid.org/0000-0001-7601-9822)
- Abinaya Seenivasan
- Reem Elfeky (ORCID: https://orcid.org/0000-0001-9382-150X)
- Jessica Laxaman
- M Davis
- Ellie Simmonds
- Arlene Barcenilla
Institutions
- Royal Free London NHS Foundation Trust (GB)
- King's College London (GB)
- South London and Maudsley NHS Foundation Trust (GB)
- Trinity College Dublin (IE)
- University of Cambridge (GB)
- Great Ormond Street Hospital (GB)
- Great Ormond Street Hospital for Children NHS Foundation Trust (GB)
- Hertfordshire Community NHS Trust (GB)
- Cambridgeshire and Peterborough NHS Foundation Trust (GB)
- Evelina London Children's Healthcare (GB)
- Royal Manchester Children's Hospital (GB)
- Institute of Infection and Immunity (CA)
- University College London (GB)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-11-19
- DOI
- https://doi.org/10.3389/fimmu.2026.2022809
- Primary Topic
- Down syndrome and intellectual disability research
- Type
- article
- Field-Weighted Citation Impact
- 0.00